| Literature DB >> 23758907 |
Carolina Valencia, Lindsay L Kindler, Roger B Fillingim, Steven Z George.
Abstract
BACKGROUND: Several chronic pain populations have demonstrated decreased conditioned pain modulation (CPM). However there is still a need to investigate the stability of CPM paradigms before the measure can be recommended for implementation. The purpose of the present study was to assess whether shoulder pain intensity and gender influence CPM stability within and between sessions.Entities:
Mesh:
Year: 2013 PMID: 23758907 PMCID: PMC3682910 DOI: 10.1186/1471-2474-14-182
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Demographic characteristics, CPM ratings, absolute change and percent change of CPM for clinical and healthy cohorts
| Age | 43.83 (17.80) | | | | |
| Sex (Female) | 47 (35.1%) | | | | |
| (Male) | 87 (64.9%) | | | | |
| BPI sess 1 (pre surgery) | 3.28 (2.31) | | | | |
| BPI sess 2 (3 months) | 1.56 (1.55) | | | | |
| Pre CPM trial 1 (pre surgery) | | 28.75 (23.39) | 64.30 (27.39) | 8.11 (11.78) | 23.9% |
| Post CPM trial 1 (pre surgery) | | 20.38 (20.99) | | | |
| Pre CPM trial 2 (pre surgery) | | 23.69 (19.99) | 62.81 (27.71) | 4.66 (8.23) | 22.9% |
| Post CPM trial 2 (pre surgery) | | 18.96 (19.69) | | | |
| Pre CPM trial 1 (3 months) | | 23.86 (17.35) | 62.69 (27.56) | 6.51 (9.33) | 36.8% |
| Post CPM trial 1 (3 months) | | 17.45 (17.81) | | | |
| Pre CPM trial 2 (3 months) | | 19.51 (16.60) | 62.13 (27.73) | 4.18 (10.02) | 9.6% |
| Post CPM trial 2 (3 months) | | 15.33 (16.00) | | | |
| Age | 23.02 (6.04) | | | | |
| Sex (Female) | 116 (61.1%) | | | | |
| (Male) | 74 (38.9%) | | | | |
| BPI day 1 | 0.45 (0.77) | | | | |
| BPI day 2 | 2.05 (1.04) | | | | |
| BPI day 3 | 2.44 (1.71) | | | | |
| BPI day 5 | 1.23 (1.21) | | | | |
| Pre CPM trial 1(day 1) | | 20.81 (20.45) | 50.19 (27.77) | 9.06 (11.51) | 48.4% |
| Post CPM trial 1 (day 1) | | 11.75 (14.91) | | | |
| Pre CPM trial 2 (day 1) | | 18.09 (18.87) | 50.88 (27.29) | 7.08 (10.35) | 46.4% |
| Post CPM trial 2 (day 1) | | 11.01 (15.14) | | | |
| Pre CPM trial 1 (day 3) | | 20.30 (19.43) | 53.97 (27.66) | 9.08 (12.74) | 46.6% |
| Post CPM trial 1 (day 3) | | 11.21 (14.54) | | | |
| Pre CPM trial 2 (day 3) | | 17.66 (18.46) | 52.70 (27.11) | 6.99 (11.09) | 41.0% |
| Post CPM trial 2 (day 3) | | 10.67 (13.52) | | | |
| Pre CPM trial 1 (day 5) | | 19.97 (20.61) | 54.37 (28.05) | 8.60 (13.38) | 41.7% |
| Post CPM trial 1 (day 5) | | 11.37 (14.24) | | | |
| Pre CPM trial 2 (day 5) | | 16.95 (18.04) | 51.96 (27.98) | 6.27 (9.99) | 39.6% |
| Post CPM trial 2 (day 5) | 10.69 (14.39) | ||||
Absolute change and percent change of CPM stratified by sex for clinical and healthy cohorts
| | ||||
|---|---|---|---|---|
| CPM trial 1 (pre surgery) | 8.56 (11.39) | 34.1% | 8.86 (12.04) | 18.9% |
| CPM trial 2 (pre surgery) | 3.94 (7.80) | 21.1% | 5.06 (8.47) | 23.8% |
| CPM trial 1 (3 months) | 4.97 (9.22) | 40.3% | 7.04 (9.37) | 35.6% |
| CPM trial 2 (3 months) | 2.72 (7.77) | 1.2% | 4.69 (10.70) | 12.3% |
| CPM trial 1 (day 1) | 9.11 (11.56) | 44.7% | 8.96 (11.50) | 54.0% |
| CPM trial 2 (day 1) | 7.42 (11.98) | 41.5% | 6.55 (7.10) | 54.0% |
| CPM trial 1 (day 3) | 10.05 (13.87) | 50.9% | 7.62 (10.67) | 39.6% |
| CPM trial 2 (day 3) | 8.11 (13.13) | 41.9% | 5.27 (6.61) | 39.7% |
| CPM trial 1 (day 5) | 9.87 (14.81) | 37.8% | 6.66 (10.67) | 47.8% |
| CPM trial 1 (day 5) | 6.57 (10.17) | 38.6% | 5.81 (9.77) | 41.2% |
Stability estimates for CPM within and between sessions for the overall sample
| Within session | CPM trial 1-CPM trial 2 (baseline) | 0.54 (0.34-0.68) | 0.42 (0.16-0.59) | 6.79 | 18.82 |
| CPM trial 1-CPM trial 2 (3 months) | 0.62 (0.43-0.74) | 0.07 (-0.51-0.36) | 5.96 | 16.52 | |
| Within session | CPM trial 1-CPM trial 2 (day 1) | 0.66 (0.55-0.75) | 0.60(0.46-0.70) | 6.37 | 17.66 |
| CPM trial 1-CPM trial 2 (day 3) | 0.72 (0.62-0.79) | 0.55 (0.39-0.67) | 6.30 | 17.46 | |
| CPM trial 1-CPM trial 2 (day 5) | 0.70 (0.60-0.78) | 0.64 (0.51-0.73) | 6.40 | 17.74 | |
| Between session | CPM trial 1 (day1)-CPM trial 1 (day3)-CPM trial 1 (day5) | 0.71(0.62-0.77) | 0.61 (0.49-0.70) | 6.75 | 18.71 |
| CPM trial 2 (day1)-CPM trial 2 (day3)-CPM trial 2 (day5) | 0.68 (0.60-0.76) | 0.59 (0.46-0.69) | 5.93 | 16.44 | |
*SEM and MDC were calculated using ICC’s for the absolute difference of CPM.
Stability estimates for CPM within and between sessions stratified by sex for clinical and healthy cohorts
| | | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Within session | CPM trial 1-CPM trial 2 (baseline) | 0.63 (0.33-0.80) | 0.57 (0.19-0.78) | 5.83 | 16.16 | 0.49 (0.21-0.67) | 0.39 (0.05-0.61) | 7.33 | 20.32 |
| CPM trial 1-CPM trial 2 (3 months) | 0.75 (0.43-0.89) | 0.73 (0.36-0.89) | 4.25 | 11.78 | 0.58 (0.32-0.73) | 0.41 (-0.03-0.66) | 6.50 | 18.02 | |
| | |||||||||
| Within session | CPM trial 1-CPM trial 2 (day 1) | 0.60 (0.42-0.72) | 0.55 (0.34-0.69) | 7.45 | 20.65 | 0.79 (0.67-0.87) | 0.66 (0.45-0.79) | 4.26 | 11.81 |
| CPM trial 1-CPM trial 2 (day 3) | 0.71 (0.57-0.80) | 0.61 (0.42-0.74) | 7.28 | 20.18 | 0.74 (0.58-0.84) | 0.52 (0.22-0.71) | 4.40 | 12.20 | |
| CPM trial 1-CPM trial 2 (day 5) | 0.64 (0.47-0.75) | 0.74 (0.61-0.82) | 7.49 | 20.76 | 0.83 (0.73-0.89) | 0.48 (0.13-0.68) | 4.21 | 11.66 | |
| Between session | CPM trial 1 (day1)-CPM trial 1 (day3)-CPM trial 1 (day5) | 0.65 (0.51-0.75) | 0.62 (0.47-0.73) | 7.93 | 21.98 | 0.82 (0.73-0.88) | 0.60 (0.40-0.75) | 4.64 | 12.86 |
| CPM trial 2 (day1)-CPM trial 2 (day3)-CPM trial 2 (day5) | 0.63 (0.49-0.74) | 0.61 (0.46-0.73) | 7.15 | 19.82 | 0.82 (0.74-0.88) | 0.58 (0.35-0.74) | 3.32 | 9.20 | |
*SEM and MDC were calculated using ICC’s for the absolute difference of CPM.
Figure 1Significant difference between the absolute difference of within session (trial 1 vs trial 2) before the surgery (session 1) and 3 months after the surgery for the clinical cohort.
Figure 2Significant difference between the absolute difference of within session (trial 1 vs trial 2) on day 1, day 3, and day 5 for the healthy cohort.
Figure 3Significant difference between the absolute difference of between sessions (day 1, day 3, and day 5) for the healthy cohort.